What is the iLink corneal cross-linking procedure and why is it central to GKOS's growth?

ILink is Glaukos's corneal cross-linking system, a procedure designed to halt the progression of keratoconus, a degenerative eye condition in which the cornea thins and bulges outward, progressively impairing vision. The procedure involves applying a riboflavin (vitamin B2) solution to the cornea and then activating it with ultraviolet-A light, which strengthens corneal collagen and slows or stops the disease's advance. iLink is central to Glaukos's growth because it generates a per-procedure consumable revenue stream: each treatment requires a single-use riboflavin solution, creating a recurring revenue model rather than a one-time capital equipment sale. Keratoconus is typically diagnosed in adolescence or early adulthood, and treatment earlier in disease progression is associated with better outcomes, meaning the addressable patient population is substantial. As physician awareness of the procedure grows and reimbursement pathways mature in various markets, the volume of iLink procedures has expanded significantly, driving much of the company's recent top-line acceleration.

What did Glaukos report in its Q3 2026 earnings and why did the stock move so sharply?

Glaukos reported Q3 2026 net sales of $211.0 million, representing 58% year-over-year growth, and non-GAAP diluted earnings per share of $0.47. Both figures materially exceeded consensus analyst expectations: revenue came in roughly $43 million above the approximately $168 million analysts had projected, and the EPS outcome reversed an anticipated adjusted loss of $0.10 per share. The combination of a substantial revenue beat, a positive earnings surprise, and a large upward revision to full-year guidance in the same release gave investors multiple simultaneous reasons to reassess the company's near-term trajectory. Sharp stock moves after earnings typically reflect the degree of surprise relative to prior expectations, and in this case the gap between reported and expected figures across both revenue and profitability was wide. For CFD traders, such post-earnings volatility illustrates the importance of understanding position sizing and liquidation risk, particularly given the leverage available on instruments like the GKOS CFD on CoinUnited.

What is Glaukos's 2026 full-year revenue guidance after the Q3 2026 update?

Following the Q3 2026 results release, Glaukos raised its full-year 2026 net-sales guidance to a range of $775 million to $785 million. This represented a significant increase from the prior guidance range of $680 million to $700 million, a raise of roughly $85 million at the midpoint. The revision reflects the pace of iLink procedure volume growth and the broader momentum across the company's ophthalmology portfolio. Guidance midpoints and ranges are forward-looking estimates provided by company management and are subject to revision based on actual business performance, reimbursement trends, competitive dynamics, and macroeconomic conditions. Investors and analysts typically use full-year guidance as a baseline for modeling growth trajectories and valuation multiples, so the size and direction of a guidance change can have an outsized effect on market sentiment. The raised range implies a meaningful acceleration in annual revenue relative to prior years, which the company attributed in large part to corneal health product demand.

What is Glaukos's preliminary 2027 revenue target and what does it imply for growth?

No verified 2027 preliminary revenue target for Glaukos was included in the available research context for this page. Providing a figure without a confirmed source would risk misstating management's actual forward guidance. For the most current long-range targets, the company's investor relations materials, earnings call transcripts, and any investor day presentations are the appropriate primary sources. What can be said is that the trajectory implied by the 2026 guidance raise, from an earlier range of $680–$700 million to $775–$785 million, suggests meaningful growth momentum. Any preliminary multi-year targets, if issued, would typically be evaluated against the backdrop of procedure volume trends in corneal cross-linking, glaucoma device adoption rates, international market expansion, and reimbursement developments. Readers should consult Glaukos's official investor relations disclosures for the most accurate and current forward-looking financial targets.

How does GKOS's gross margin compare to other medical device companies?

The research context available for this page does not include a specific gross margin figure for Glaukos or a direct peer comparison, so no precise percentage can be stated here without risking an invented statistic. As a general structural observation, medical device companies that combine proprietary consumables with a per-procedure revenue model tend to carry different margin profiles than those reliant primarily on capital equipment sales, because high-margin single-use components can support strong recurring gross margins once initial infrastructure is in place. Glaukos's iLink riboflavin solutions fit this consumable model. The ophthalmology device sector broadly includes companies at varying stages of growth and scale, and gross margin comparisons are most meaningful when controlling for revenue size, product mix, and geographic revenue distribution. For Glaukos's current gross margin figures, the company's most recent earnings release and SEC filings are the appropriate sources, as those numbers are updated quarterly and any figure stated here would be subject to revision.

Does Glaukos Corporation pay a dividend?

Glaukos Corporation does not currently pay a dividend, which is common for growth-stage medical device companies that prioritize reinvesting capital into research, product development, commercial expansion, and pipeline advancement over returning cash to shareholders. Companies at Glaukos's stage of commercial maturity typically use available cash to fund clinical trials, geographic market expansion, and potential acquisitions rather than dividend distributions. This is worth noting for income-oriented investors evaluating the stock. It is also worth noting that the CoinUnited GKOS instrument is a CFD, meaning it tracks the price of the underlying shares but does not confer any ownership stake, voting rights, or entitlement to dividends. Even if Glaukos were to initiate a dividend in the future, holders of the GKOS CFD on CoinUnited would not receive it, as CFD positions represent price exposure only. Dividend policy can change over time and should be verified against the company's most current investor relations disclosures.

What is Glaukos's debt situation and how much cash does it hold?

The research context provided for this page does not include specific figures for Glaukos's current debt levels or cash and equivalents on hand, so no balance sheet figures can be stated here without the risk of presenting unverified numbers. For precise and current data on Glaukos's liquidity position, debt obligations, and cash reserves, the company's most recent quarterly report filed with the SEC is the appropriate reference. Generally speaking, the capital structure of a medical technology company at a high-growth stage is relevant to assessing financial risk: the proportion of debt relative to cash and projected operating cash flow affects the company's flexibility to fund pipeline investment and weather revenue shortfalls. Given Glaukos's recent revenue acceleration, investor attention to its balance sheet typically focuses on whether operating cash flow is trending toward covering its investment and financing needs. Current and prospective CFD traders on CoinUnited should review the company's official filings for the most accurate financial position data before forming any view.

What are the main risks of investing in or trading GKOS?

GKOS carries several distinct risk categories that traders and investors should understand before taking a position. As a medical device company, Glaukos depends heavily on regulatory approvals, reimbursement decisions by insurers and government payers, and continued physician adoption of its corneal cross-linking and glaucoma procedures. Any adverse change in those areas can materially affect revenue. The stock also reflects significant growth expectations, which means results that merely meet rather than exceed estimates can still trigger price declines. Clinical trial outcomes, intellectual property disputes, and competitive entries into the ophthalmology market are additional company-specific risks. On the macro side, rising interest rates and broader equity market volatility can weigh on high-growth medical device valuations. For those trading GKOS as a CFD on CoinUnited, leverage amplifies both gains and losses relative to the initial margin, and positions can be liquidated if the market moves against a trader's position. The instrument also follows a scheduled trading session and is closed at weekends and on market holidays, meaning adverse news released outside session hours can produce gap moves when the market reopens.

How does reimbursement policy affect Glaukos's revenue and stock price?

Reimbursement coverage is a central commercial driver for Glaukos because its two core product lines, corneal cross-linking (iLink) and minimally invasive glaucoma surgery devices, require payer approval before most patients can access them affordably. When insurers, Medicare, or Medicaid expand or restrict coverage for these procedures, the addressable patient population and procedure volumes shift directly, with immediate implications for quarterly revenue. Expansion of iLink reimbursement to new patient segments or geographies has historically correlated with accelerating revenue growth. Conversely, any reimbursement denial or reimbursement-rate reduction can stall adoption even where the clinical case for the procedure is strong, because hospitals and physician practices weigh reimbursement rates when deciding whether to invest in the necessary capital equipment and staff training. For GKOS equity, reimbursement announcements can function as binary events, producing sharp price moves in either direction. Because much of the company's valuation reflects future procedure-volume assumptions, any policy change that revises those assumptions upward or downward tends to be reflected quickly in the stock price.

Who are Glaukos Corporation's main competitors in ophthalmology?

Glaukos operates in two distinct ophthalmic segments, each with its own competitive landscape. In corneal health, iLink (corneal cross-linking for keratoconus) has benefited from first-mover advantage in the United States, but other companies have developed or are developing cross-linking systems, and generic or compounded riboflavin formulations represent a lower-cost alternative that some practitioners use off-label. In glaucoma, Glaukos competes with established surgical device makers offering micro-stents, trabecular bypass devices, and aqueous drainage implants. Larger ophthalmology-focused companies as well as diversified medical device firms have product lines targeting mild-to-moderate open-angle glaucoma, the same patient population Glaukos's MIGS portfolio addresses. Pharmaceutical therapies, topical eye drops for glaucoma pressure control, also represent indirect competition, since a patient well-managed on drops may not be referred for surgical intervention. The competitive position of any single Glaukos product can shift with new clinical data, regulatory approvals for rival devices, or pricing changes in the broader ophthalmic surgical market.

What analyst price targets exist for GKOS following Q3 2026 earnings?

The research context available for this page does not include specific analyst price targets issued after Glaukos's Q3 2026 earnings release, so no named targets or specific figures can be stated here without risking inaccuracy. What the verified data does show is that Q3 2026 net sales of $211.0 million substantially exceeded analyst revenue expectations of approximately $168.0 million, and non-GAAP diluted earnings per share of $0.47 compared with analyst expectations for an adjusted loss of $0.10 per share. When results deviate from consensus by those margins, it is common for sell-side analysts to revise their price targets and earnings models upward. The degree of revision typically reflects how much of the beat analysts attribute to durable factors, such as iLink reimbursement expansion, versus one-time items. Full-year guidance was also raised materially, which tends to anchor revised target calculations. For current, specific analyst price targets on GKOS, financial data terminals, the investor relations section of the Glaukos website, and regulated financial news services are the appropriate sources to consult.

Why did GKOS shares rise roughly 19.6% after hours in October 2026?

The after-hours move followed Glaukos's Q3 2026 earnings release on October 28, 2026, which contained results that significantly exceeded analyst expectations on multiple dimensions. Net sales of $211.0 million were up 58% year over year and came in well above the analyst consensus estimate of approximately $168.0 million. Non-GAAP diluted earnings per share of $0.47 compared with analyst expectations for an adjusted loss of $0.10 per share, a swing from an anticipated loss to a meaningful profit. Glaukos also raised its full-year 2026 net-sales guidance to a range of $775 million to $785 million, up from the prior range of $680 million to $700 million. Guidance revisions of that magnitude signal that management has high confidence in the demand trajectory, particularly for iLink, and they force analysts to revise their full-year and forward-year models upward simultaneously. When revenue, earnings, and guidance all surprise positively in the same report, the cumulative effect on stock price tends to be magnified, because each element independently triggers model revisions and sentiment shifts. The scale of the beats relative to consensus was large enough that the after-hours reaction reflected a broad reassessment of near-term and medium-term earnings power.

What is keratoconus and how large is the addressable patient population for iLink?

Keratoconus is a progressive eye condition in which the cornea gradually thins and bulges into a cone-like shape, distorting vision and, in severe cases, requiring corneal transplantation. It typically manifests in adolescence or early adulthood and can worsen through a patient's thirties. The condition affects visual acuity in ways that spectacles and standard contact lenses often cannot fully correct as it advances. Corneal cross-linking, the procedure category in which Glaukos's iLink system operates, is designed to halt the progression of keratoconus by strengthening corneal tissue using riboflavin eye drops and ultraviolet light. It does not reverse existing corneal distortion but aims to prevent further deterioration, making early diagnosis and treatment particularly important. The research context available for this page does not include a specific verified figure for the global or domestic keratoconus patient population, so no precise addressable market number is stated here. Glaukos has described keratoconus as a significant underdiagnosed condition, implying that improved screening and expanded reimbursement could meaningfully expand the treated population beyond current levels. The commercial opportunity for iLink therefore depends partly on diagnosis rates and partly on reimbursement access.

How does GKOS perform relative to the S&P 500 over a one-year period?

Direct one-year return comparisons require a specific starting price for GKOS, which this page does not include since live prices are displayed separately. What the research context provides is the S&P 500 index level of 7,743.98 as of October 28, 2026, which can serve as a reference point for the broader market backdrop against which GKOS's performance is measured. Glaukos is classified as a mid-to-large-cap medical device company, a segment whose performance relative to the broad index tends to be driven by its own clinical and commercial milestones rather than macro factors alone. The Q3 2026 earnings release, which produced a large after-hours price move, illustrates how company-specific events can decouple GKOS's short-term trajectory from broader index movements. For a precise one-year return comparison, financial data services that calculate total return (including any dividends, though Glaukos does not currently pay one) relative to the S&P 500 over a defined trailing period are the appropriate tools. Performance relative to the index over any single period does not predict future relative performance.

What is a GKOS CFD and how does it differ from owning Glaukos shares?

A GKOS CFD on CoinUnited is a contract that provides price exposure to Glaukos Corporation stock without transferring ownership of the underlying shares. The position tracks the price movements of GKOS equity, but it confers no shareholding, no voting rights at shareholder meetings, and no entitlement to dividends. A trader profits or loses based on the direction and magnitude of price movement relative to the entry level. The structural difference from direct share ownership is significant. Owning Glaukos shares means holding a fractional equity interest in the company, with all associated corporate rights and the ability to hold the position through any market environment without a mandatory margin requirement. A CFD position is a derivative contract that requires margin and carries liquidation risk if the market moves adversely beyond the margin buffer. CoinUnited's GKOS CFD supports leverage up to 1000x, subject to product, jurisdiction, and account eligibility conditions. Because leverage amplifies both gains and losses, a small adverse price move can result in losses that exceed the initial margin, potentially triggering liquidation. The instrument follows a scheduled trading session and is closed at weekends and on market holidays; the session calendar is available on the platform before trading. Fees are tiered by 30-day contract volume across nine VIP levels and are not zero at the standard tier; the full schedule is at https://coinunited.io/en/account/trading-fees. Accounts are funded and withdrawn in crypto, with no traditional bank account required.

How does leverage work when trading GKOS as a CFD on CoinUnited?

A GKOS CFD on CoinUnited provides price exposure to Glaukos Corporation without requiring ownership of the underlying shares. The CFD tracks the market price of GKOS, so gains and losses reflect price movement relative to the notional position size, not the margin deposited. The maximum leverage available on this instrument is 1000x, subject to product, jurisdiction, and account eligibility conditions. To illustrate the arithmetic: a $1,000 margin position at 1000x controls a $1,000,000 notional exposure. A 1% move in the GKOS price would therefore produce a $10,000 gain or loss, which is ten times the initial margin. This amplification works in both directions. Losses can exceed the margin deposited, and positions can be liquidated if the account falls below the required maintenance threshold. Given GKOS's recent history of sharp single-session moves, the stock rose approximately 19.6% after hours following Q3 2026 earnings, the interaction between leverage and event-driven volatility deserves careful consideration before a position is opened.

What is the gap risk for GKOS CFD positions held over weekends or into earnings?

Gap risk is the possibility that the GKOS price reopens at a materially different level than where it closed, bypassing any stop-loss orders set at intermediate prices. Because the GKOS CFD follows a scheduled trading session and is closed at weekends and on market holidays, positions carried into those closures are exposed to any news, filings, or macro developments that emerge while the market is shut. Glaukos's Q3 2026 results illustrate the scale of this risk concretely. The company reported net sales of $211.0 million against analyst expectations of approximately $168.0 million, and non-GAAP diluted EPS of $0.47 versus consensus expectations for a loss of $0.10. The after-hours reaction was a move of roughly 19.6%. A CFD position held into that close would have gapped to a re-open price reflecting those figures, with stop-loss orders potentially unable to execute at the intended level. Earnings dates and other scheduled disclosures are therefore a specific category of gap risk for GKOS, separate from general weekend closure risk.

How are trading fees structured for the GKOS CFD on CoinUnited?

Trading fees on the GKOS CFD are not zero at the standard tier. CoinUnited applies a tiered fee schedule based on 30-day contract volume, with nine VIP levels. The rate declines as cumulative volume rises, reaching 0.000% only at VIP 9, which requires 30-day contract volume of 20,000,000,000 USDT or an account balance of 200,000,000 USDT. Most accounts will trade at a rate above zero. Because the live fee rate for your account tier is rendered directly on the trading page, no specific percentage is stated here, any figure written into an article would become stale whenever the schedule is updated. The full tier structure, volume thresholds, and the applicable rate for each level are published at https://coinunited.io/en/account/trading-fees. Reviewing that schedule before placing a trade gives the most accurate cost picture, particularly for strategies that involve frequent entries and exits where cumulative fees can have a meaningful effect on net returns.

When is the GKOS CFD instrument open for trading on CoinUnited?

The GKOS CFD follows a scheduled trading session tied to the underlying equity market. It is closed at weekends and observes market holidays. Trading is therefore not continuous, and the instrument is unavailable during those closure periods. The precise session times and the holiday calendar for this instrument are displayed on the CoinUnited platform before you place an order. This session structure has direct practical consequences. News relevant to Glaukos, such as earnings releases, FDA decisions on iLink reimbursement, or broader medical-device sector developments, can emerge outside trading hours, including over weekends. When the session reopens, the price may reflect a significant adjustment relative to the prior close, creating gap risk for open positions. Checking the platform for the applicable session schedule is a straightforward way to understand when orders can be placed and when existing positions are exposed to overnight or weekend closure risk.

Diğer Kripto Paralara Git

GKOSGlaukos Corporation

Hızlı Bağlantılar

Pozisyon Hesaplayıcı

Pozisyon Boyutu (USD)Kaldıraç

Gerekli Marj

$10.00

GKOS hareket ederse P&L

+1%+$10.00

+5%+$50.00

+10%+$100.00

1000x Kaldıraç ile Ticaret Yapmaya Başlayın

GKOSGlaukos Corporation · 1000xŞimdi İşlem Yap

Glaukos Corporation

GKOS

$220.04

-11.25% (24h)

Hisse SenetleriSeviye CCoinUnited.io'da işlem görür1000x Kaldıraç

Şimdi GKOS Ticaret Yapın

Today's SignalNext earnings2027-02-16Latest quarter revenue$211MQ3 2026Gross margin85.2%Q3 2026

How can you trade Glaukos Corporation? Glaukos Corporation (GKOS) is publicly listed. On CoinUnited, eligible users can trade a GKOS stock CFD — price exposure that tracks the share price. It is a price CFD, not equity (no shareholder voting; dividends reflected as an adjustment) — with leverage, from US$100. Access terms vary by jurisdiction and product eligibility.

How to trade it

Trading stock CFDs on CoinUnited + strategy

Ticaret Rejimi Durumu

Kaldıraç

1000x

(CoinUnited.io'da maksimum)

Volatilite

Aşırı

(13.82% 24h)

How the GKOS CFD works

Before you trade, understand exactly what you get, what you don't, and where the risk sits.

What you buy

Price exposure to the GKOS reference (a synthetic CFD) that tracks the CoinUnited reference up and down.

What you do NOT get

It is not equity: no shares, no voting rights; dividends are reflected as an adjustment, not paid to you.

Basis / session risk

The CoinUnited reference tracks the share price but can differ from the exchange price; extended-hours liquidity is thinner.

Leverage illustration: with $100 margin at 1000× leverage you open a $100,000 notional position; if price moves against you to the liquidation level the position is force-closed. High leverage magnifies both profit and liquidation risk.

Trading conditions on CoinUnited

Fee schedule as of 2026-08-19

Product type	CFD	Synthetic price exposure. You do not hold the underlying asset.
Trading fee	0,070%	Per side, at the standard tier. Falls with 30-day volume and reaches 0.000% at VIP 9.
Trading hours	Market session	Follows the market session and is closed at weekends and on market holidays.
Kaldıraç - gün içi	1.000x	Aktif işlem saatleri içinde geçerlidir. En küçük pozisyon büyüklüğünde 0,050% teminat gerektirir. Kullanılabilirlik ve üst sınır; ürüne, yetki alanına ve hesap uygunluğuna göre değişir; kaldıraç zararları büyütür ve pozisyonlar likide edilebilir.
Kaldıraç - gecelik	10x	İşlem günü sonrasına taşınan pozisyonlar için geçerlidir. En küçük pozisyon büyüklüğünde 5,000% teminat gerektirir.
Kaldıraç - hafta sonu ve tatiller	10x	Piyasa kapalıyken taşınan pozisyonlar için geçerlidir. En küçük pozisyon büyüklüğünde 5,000% teminat gerektirir - pozisyonunuzu hafta sonuna taşımadan önce büyüklüğünü kontrol edin.
Direction	Long or short	Take a position in either direction. A short position profits when the price falls and loses when it rises.
Funding	Crypto deposit	Fund and withdraw in crypto. No bank transfer or card is required.

See the full fee schedule →

Trading GKOS on CoinUnited.io: CFD Mechanics, Position Sizing, and Risk Management

The GKOS instrument on CoinUnited is a CFD: it provides leveraged price exposure to Glaukos Corporation's share price without conferring any shareholding, voting rights, or dividend entitlement. Positions are settled in USDT. Accounts are funded and withdrawn via crypto, so no traditional bank account or paperwork is required.

How the CFD Instrument Works

A CFD position opens and closes against the prevailing market price of the underlying GKOS equity. The trader's profit or loss equals the price change across the position's notional size, minus applicable trading fees. CoinUnited charges a trading fee on this instrument; it is not zero at the standard tier.

Fees are tiered across nine VIP levels by 30-day contract volume, reaching 0.000% only at VIP 9, which requires 30-day volume of 20,000,000,000 USDT or a balance of 200,000,000 USDT. The full tiered schedule is at coinunited.io/en/account/trading-fees.

The instrument's maximum leverage is 1000x, subject to product, jurisdiction, and account eligibility. Leverage amplifies both gains and losses proportionally and can trigger liquidation. This is a specification, not a recommendation; traders should assess their own risk tolerance before selecting any leverage level.

Worked Leverage Example

The following is a hypothetical illustration of 1000x mechanics. All figures are exact given the stated inputs.

Input	Value
Margin allocated	$100 USDT
Leverage	1000x
Notional exposure	$100,000
Adverse move (1%)	−$1,000 loss
Favorable move (1%)	+$1,000 gain

Step by step:

Margin × leverage = notional: $100 × 1,000 = $100,000
A 1% adverse price move on $100,000 notional = $1,000 loss
The $1,000 loss exceeds the $100 margin by ten times, triggering liquidation unless additional margin is posted promptly
The same 1% favorable move produces a $1,000 gain, leverage is symmetric in both directions

This example uses a routine 1% daily move. GKOS has demonstrated single-session price moves far exceeding that threshold, which is addressed below.

Session Structure and Gap Risk

The GKOS CFD follows a scheduled trading session. It is closed at weekends and observes market holidays. The session times and holiday calendar are displayed on the platform before order entry. This schedule creates a specific risk category: gap openings.

Any corporate announcement, FDA decision, or macro development occurring while the session is closed will be reflected in the price at the next session open. A stop-loss order placed before the close may not execute at its intended level if the opening price has already moved through it.

The Q3 2026 earnings release, reported on October 28, 2026, produced an after-hours move of approximately 19.6% following results that significantly exceeded analyst expectations across revenue and EPS. A position sized for a 2% routine swing would have faced full liquidation exposure from a move of that magnitude.

Position Sizing Around Earnings

For a stock with demonstrated earnings-period volatility of this scale, position sizing based on routine daily ranges is structurally inadequate during reporting windows. A practical framework:

-Identify the realistic adverse scenario: for GKOS, historical single-session moves suggest a gap of 15–20% or more is plausible around earnings
-Size margin so that the maximum adverse move scenario results in a loss the account can absorb, not automatic liquidation
-Reducing leverage materially below the instrument maximum widens the price move required to reach the liquidation threshold
-Carrying a leveraged position through a session close ahead of a scheduled earnings date means accepting gap risk that cannot be managed with intra-session stop mechanics

No position size eliminates the risk of a gap exceeding the margin posted; it can only be reduced by lowering notional exposure relative to margin, or by closing the position before the session closes ahead of a known catalyst.

⚡1000x💰Fees down to 0%⏱️10s Start

GKOS ile İşlem Yapmaya Hazır Mısınız?

1000x'e kadar kaldıraç

Şimdi GKOS Ticaret Yapın

Key facts & how to trade

The essentials + how you access it on CoinUnited

Access & Tradability Comparison

A CoinUnited stock CFD vs holding the underlying shares — how, when, and in what form you get exposure. The stock price is everywhere; this comparison is the differentiator.

Terms	CoinUnited (CFD)	Holding shares (exchange)
Product form	Stock CFD (price exposure)	Equity ownership
Trading hours	Market session	Exchange regular hours
Leverage	Available (by product terms)	None / margin account needed
Shareholder rights	None (no voting; dividends as adjustment)	Voting + dividends
Access	Eligible users, by region + product	Brokerage account required

*Access and minimum vary by jurisdiction and product eligibility.

Temel bilgiler

Bu şirket hakkında en çok alıntılanan veriler, her biri kaynağıyla birlikte: okuyucular ve yapay zekâ yanıt motorları için hızlı başvuru kutusu.

Genel merkez	San ClementeWikidata
Halka açıklık durumu	Halka açık: GKOSExchange
Piyasa değeri	$14B (as of 2026-11-01)CoinUnited reference x SEC shares
52 haftalık aralık	$228.02 – $247.91CoinUnited daily kline
Sonraki bilanço	2027-02-16Finnhub
CoinUnited ürünü	Hisse senedi CFD'si - yalnızca fiyat maruziyeti, hisse mülkiyeti değil (oy hakkı yoktur; temettüler düzeltme olarak yansıtılır); kaldıraç mevcuttur.CoinUnited ürün koşulları

Fiyat & Piyasa Yapısı

24S Aralık: $218.57→$248.99

24S Düşük

$218.57

24S Yüksek

$248.99

TEKLİF / SATIŞ

$219.57 / $220.51

Grafik yükleniyor...

Company & financials

Business model + audited SEC financials

What Is Glaukos Corporation (GKOS)?

TL;DR

Glaukos Corporation is a US ophthalmic medical device company that delivered 58% year-over-year revenue growth in Q3 2026, raised its full-year 2026 guidance substantially, and introduced preliminary 2027 net-sales guidance of approximately $1 billion, reflecting the rapid commercial adoption of its iLink corneal health platform.

Glaukos Corporation is a US-based ophthalmic medical device and pharmaceutical company specializing in interventional treatments for two distinct clinical areas: glaucoma and corneal health. The company develops, manufactures, and commercializes minimally invasive surgical devices alongside pharmaceutical therapies and procedure-based platforms.

Its corneal health segment, anchored by the iLink corneal cross-linking platform, has become the primary engine of revenue growth in recent periods.

Business Model and Financial Scale

Glaukos operates what is largely a procedure-and-consumable model: clinicians use its proprietary devices and single-use components in a recurring workflow, which supports durable pricing and high gross margins.

As of Q3 2026, the company reported a GAAP gross margin of approximately 85% and a non-GAAP gross margin of approximately 88%, reflecting the pricing characteristics typical of specialized ophthalmic procedures rather than commodity medical equipment.

In the third quarter of 2026, Glaukos reported net sales of $211.0 million, a 58% increase over the same quarter in the prior year. That result exceeded analyst expectations of approximately $168 million for the period.

Following this performance, the company raised its full-year 2026 net-sales guidance to a range of $775 million to $785 million, a material revision upward from its prior guidance of $680 million to $700 million.

Balance Sheet and Profitability Trajectory

As of September 30, 2026, Glaukos carried no debt and held approximately $339.8 million in cash, cash equivalents, short-term investments, and restricted cash. This net-cash position provides operational flexibility without the constraint of debt-service obligations.

On the profitability front, Q3 2026 GAAP net income was approximately $2.0 million. This marks a clear improvement from a GAAP net loss of $16.2 million in the equivalent quarter of the prior year, indicating the company's progression toward sustained GAAP profitability.

Non-GAAP diluted earnings per share reached $0.47 in the quarter, compared with analyst expectations for an adjusted loss of $0.10 per share.

What a GKOS CFD Tracks

The Glaukos instrument available on CoinUnited is a CFD position, leveraged price exposure that tracks the underlying GKOS equity market. It does not confer any shareholding, voting rights, or entitlement to dividends. Traders gain or lose based on price movements in the underlying market.

The instrument follows a scheduled trading session and is closed at weekends; the precise session times and any applicable market holidays are displayed on the platform before a position is opened. For context on the broader equities environment in which GKOS trades, the 2026 Stocks Market Outlook provides relevant macro framing.

Son güncelleme: 2026-10-29

Anahtar Gözlemler

Glaukos's Q3 2026 non-GAAP EPS of $0.47 versus analyst expectations of a $0.10 adjusted loss represents one of the largest consensus beats in the company's reporting history, driven by the iLink corneal cross-linking platform scaling faster than the market had modeled.
The company reported no debt and approximately $339.8 million in liquid assets as of September 30, 2026, providing a balance-sheet cushion that is atypical for a mid-cap medical device company still in high-growth mode.
GAAP gross margin of approximately 85% and non-GAAP gross margin of approximately 88% in Q3 2026 indicate a largely consumable-and-procedure revenue model with pricing power, which structurally supports margin expansion as volumes scale.
The post-earnings share move of approximately 19.6% in after-hours trading illustrates the price-discovery risk unique to earnings events: large gaps can open at the session start, making pre-earnings position sizing a distinct risk management consideration for CFD traders.
Preliminary 2027 net-sales guidance of approximately $1 billion, against a revised 2026 range of $775 million to $785 million, implies management's confidence in continued double-digit growth, though guidance at this horizon carries execution and reimbursement-environment risk.

Key Financials

Audited · SEC filings

Reported figures from the company’s latest SEC filings — each linked to its source filing and period.

$211M

Quarterly revenue

Q3 2026 · SEC 10-Q

$2M

Net income

Q3 2026 · SEC 10-Q

85.2%

Gross margin

Q3 2026 · SEC 10-Q

$0.03

Diluted EPS

Q3 2026 · SEC 10-Q

Quarterly revenue

$254M

$170M

$85M

$124MQ2 2025

$134MQ3 2025

~$143MQ4 2025

$151MQ1 2026

$186MQ2 2026

$211MQ3 2026

~ Q4 is not filed as a standalone quarter — it is the annual 10-K figure minus the three filed quarters.

Figures are from the company’s audited SEC filings; each carries its filing source and period. Not investment advice.

Machine-readable table — same figures, per-metric source

Metric	Value	Source
Quarterly revenue (Q3 2026)	$211M	SEC 10-Q
Net income (Q3 2026)	$2M	SEC 10-Q
Gross margin (Q3 2026)	85.2%	SEC 10-Q
Diluted EPS (Q3 2026)	$0.03	SEC 10-Q

GKOS Competitive Position: Glaukos in the Ophthalmic Device Landscape

Glaukos occupies a deliberately narrow position within the ophthalmic device industry, concentrating almost entirely on interventional glaucoma and corneal health rather than the broader categories, retinal disease, refractive surgery, contact lenses, that define larger diversified competitors.

Understanding where Glaukos sits relative to those peers helps clarify both the opportunity and the concentration risk embedded in its equity price.

A Focused Platform in a Fragmented Sector

The ophthalmic medical device market includes companies with very different revenue compositions. Larger players typically address multiple disease categories simultaneously, spreading revenue across retinal therapeutics, intraocular lenses, surgical equipment, and consumer vision products. Glaukos does not.

Its revenue derives from two segments, interventional glaucoma, built on micro-invasive surgical devices implanted alongside cataract surgery, and corneal health, anchored by the iLink cross-linking platform used to halt the progression of keratoconus.

This focus creates a different risk-return profile. A diversified ophthalmic company is less exposed to disruption in any single procedure category, but it also captures less upside from a specific segment growing faster than the broader market.

Glaukos, by contrast, offers concentrated exposure to iLink penetration and to the continued adoption of micro-invasive glaucoma surgery, procedures still in relatively early commercial phases compared with mature markets like premium intraocular lenses.

Analyst Consensus and the Range of Views

Following the Q3 2026 results, analyst price target revisions pointed broadly in a positive direction. Piper Sandler revised its target to $240, Needham to $251, and Mizuho to $225.

The spread across those targets, approximately $26 from the lowest to the highest, reflects genuine disagreement among analysts, particularly around the pace at which iLink penetration into the keratoconus patient population will proceed and what 2027 operating margins will look like as the company scales its commercial infrastructure.

Price target ranges of this width are not unusual for a company transitioning from a device-growth story to a higher-margin platform story, but they do signal that the investment case is not settled consensus. Traders taking CFD price exposure to GKOS should account for the possibility of sharp reactions to guidance updates or procedure-volume data that tilts sentiment within that range.

Share Performance Versus Broader Equity Market

As of October 29, 2026, GKOS had recorded an approximately 135% one-year share gain, a performance that significantly outpaced the S&P 500, which stood at 7,743.98 as of October 28, 2026. That outperformance reflects a re-rating: the market appears to have reclassified Glaukos from a slower-growth glaucoma device company to a higher-growth corneal health platform business.

Re-ratings of this type can be durable if the underlying commercial thesis holds, but they also compress the margin of safety, a stock trading on an upgraded growth assumption is more sensitive to any miss against that assumption.

Balance Sheet Strength Relative to Peers

At similar revenue scales, many medtech companies carry meaningful debt, particularly those that have grown through acquisition. Glaukos, carrying no debt as of September 30, 2026, and holding approximately $339.8 million in cash and short-term investments, compares favorably on this dimension.

High gross margins, approximately 85% on a GAAP basis in Q3 2026, are also characteristic of specialized procedure platforms rather than capital-equipment or commodity device businesses.

The offset is that GAAP profitability has only recently turned positive. GAAP net income of approximately $2.0 million in Q3 2026 represents a narrow cushion. Companies at this stage of the profitability curve are more sensitive to operating expense growth than established medtech businesses with predictable, multi-decade cash flows.

A meaningful acceleration in sales-force investment, R&D spend, or regulatory costs could push GAAP results back into negative territory before scale economics fully absorb those costs.

Positioning Summary

Dimension	Glaukos (GKOS)	Diversified Ophthalmic Peers
Revenue concentration	High (glaucoma + corneal health)	Low (multi-segment)
Gross margin profile	~85% GAAP, ~88% non-GAAP (Q3 2026)	Varies; typically lower for device-heavy mix
Debt position	Zero debt (as of Sept 30, 2026)	Variable; often leveraged post-acquisition
GAAP profitability	Recently positive; narrow margin	Often established positive free cash flow
Growth exposure	Concentrated in iLink + MIGS adoption	Spread across multiple procedure categories

Traders seeking CFD price exposure to a focused ophthalmic growth platform will find GKOS structurally different from diversified medtech names. The concentration that provides upside leverage to iLink's commercial trajectory is the same concentration that amplifies downside if that trajectory disappoints.

Why Trade GKOS? Price Drivers, Catalysts, and Risk Factors

Glaukos offers traders a distinct analytical profile: a high-growth medtech company with concentrated revenue exposure to a single procedure category, identifiable near-term catalysts, and a demonstrated history of large earnings-driven price moves. The framework below organizes the key variables a trader should monitor.

The Q3 2026 Earnings Event as a Precedent

The Q3 2026 results, released October 28, 2026, illustrate the earnings-event dynamics that characterize GKOS. Non-GAAP diluted EPS of $0.47 arrived against analyst expectations for an adjusted loss of $0.10 per share, a beat of approximately $0.57 per share. Revenue of $211.03 million exceeded the consensus estimate of approximately $168.03 million by a margin of roughly 25%.

The after-hours price response was approximately 19.6%. That magnitude of move, driven by a single reporting date, is material information for any trader sizing a position around a scheduled catalyst. Holding through earnings without accounting for gap risk carries real cost; the same volatility that produces large gains can produce equivalent losses in the opposing direction.

Forward Guidance as a Persistent Price Anchor

Glaukos's preliminary 2027 net-sales guidance of approximately $1 billion provides a long-duration reference point that analyst models will be calibrated against through multiple subsequent quarters. Guidance figures of this visibility tend to anchor valuation multiples: upward revisions typically compress implied discount rates and support re-rating; downward revisions do the reverse.

Any quarterly revenue update that puts the $1 billion target in question, or demonstrates the company is tracking above it, is likely to generate a disproportionate price response relative to the headline earnings beat or miss.

Structural Demand Driver: Keratoconus and Cross-Linking Penetration

The long-run revenue case for Glaukos rests on the corneal cross-linking procedure for keratoconus. Keratoconus is a progressive corneal condition that has historically been underdiagnosed and undertreated, partly due to limited specialist access and partly due to incomplete reimbursement coverage.

The central variables for forward modeling are the size of the addressable patient population that can be reached given current diagnostic rates, and the pace at which payers in different geographies extend or standardize reimbursement.

These are slow-moving variables that compound over years, but any discrete reimbursement decision, positive or negative, can shift near-term revenue expectations materially.

Risk Factors

Four categories of risk warrant explicit attention:

Risk Category	Mechanism	Potential Price Impact
Reimbursement coverage decisions	A single adverse payer determination can reduce accessible patient volume at scale	High; changes are discrete and often binary
Competitive dynamics	Alternative corneal procedures or future entrants could pressure pricing or share	Moderate; competition timelines are uncertain
Regulatory pipeline timing	Delays or setbacks in new indication approvals extend the period before additional revenue can be recognized	Moderate to high depending on indication size
Macro and sector sensitivity	Medtech valuations correlate with interest-rate levels and healthcare policy; the US 10-year Treasury yield stood at 4.99% as of late October 2026, a level that constrains growth-stock multiples broadly	Diffuse; affects the sector, not GKOS specifically

The broader interest-rate environment is relevant context here. Elevated long-duration yields compress the present value of future cash flows, which disproportionately affects companies whose valuation reflects growth several years out. GKOS, trading on expectations of sustained high growth, carries this sensitivity as a background variable even in quarters where its own fundamentals are strong.

Traders tracking macro conditions alongside company-specific data may find the 2026 Stocks Market Outlook a useful reference for that broader framing.

Earnings Volatility as a Trading Characteristic

The Q3 2026 event is not an isolated data point, it reflects a pattern in which GKOS positions generate outsized moves around reporting dates.

For traders using CFD price exposure, this creates two distinct tactical considerations: the potential to capture a large directional move if positioned ahead of a result, and the exposure to an equally large adverse gap if the result disappoints or guidance is revised downward. Neither scenario is predictable in advance; what is predictable is that the magnitude of moves has been material.

Position sizing and stop-loss placement relative to earnings dates are therefore more consequential for GKOS than for lower-volatility instruments in the same sector.

Valuation & peers

Multiples vs peers + third-party analyst targets

Peer Valuation Comparison

How this stock trades versus comparable listed companies on trailing valuation multiples.

Company	Market cap	P/E	P/S
Glaukos Corporation · GKOS	$14.1B	—	20.4x
Alcon Inc. · ALC	$34.5B	55.0x	3.2x
Bausch + Lomb Corporation · BLCO	$7.1B	—	1.3x
Ocular Therapeutix, Inc. · OCUL	$1.5B	—	29.4x
STAAR Surgical Company · STAA	$1.2B	306.7x	3.6x
SpyGlass Pharma, Inc. Common Stock · SGP	$1.1B	—	—

Third-party ratios (FMP), trailing twelve months. Multiples vary by data window; a negative or absent P/E means the company is loss-making. Not investment advice.

Analyst Price Targets

Buy

Wall Street sell-side analysts’ consensus 12-month price target and rating for this stock.

Consensus target

$218.70-8.6%

Target range

$150.00 – $255.00

Price-target coverage

10 analysts

Analyst ratings (25)

Buy 18Hold 6Sell 1

Targets by firm

Latest target from each of the 10 firms whose call was reported in the past 180 days. Each row links to the report.

Firm	Target	vs current
H.C. Wainwright2026-10-29 · TheFly	$248.00	+3.7%
Stifel Nicolaus2026-10-29 · TheFly	$225.00	-6.0%
Piper Sandler2026-10-29 · TheFly	$240.00	+0.3%
Needham2026-10-29 · StreetInsider	$251.00	+4.9%
Mizuho Securities2026-10-29 · StreetInsider	$225.00	-6.0%
Truist Financial2026-10-29 · StreetInsider	$255.00	+6.6%
BTIG2026-10-12 · TheFly	$205.00	-14.3%
Jefferies2026-09-22 · TheFly	$210.00	-12.2%
Wells Fargo2026-07-30 · TheFly	$178.00	-25.6%
UBS2026-07-28 · TheFly	$150.00	-37.3%

Source: aggregated sell-side analyst consensus · as of 2026-11-01. These are third-party analyst opinions — not CoinUnited’s view, not a price prediction, and not investment advice.

Scenario calculator

Pick a third-party reference level and see what it implies at leverage. Reference levels only - not a CoinUnited forecast.

Scenario price

$220.04

+0.0% vs current

Your margin (USD)Leverage

Position size $100,000.00

P&L at this scenario (long)

+$0.00

Loss if liquidated -$1,000.00 (the full margin)

Liquidation price (long): $217.84 — a move of -1.0%

Şimdi GKOS Ticaret Yapın

Simplified: excludes fees, funding and slippage. Reference levels are third-party marks (CoinUnited daily kline; aggregated sell-side analyst targets), not forecasts. Leverage magnifies losses as much as gains - at high leverage a small adverse move liquidates the position. Not investment advice.

Catalysts & news

Dated third-party developments · newest first

Ana Çıkarımlar

•Glaukos's Q3 2026 non-GAAP EPS of $0.47 versus analyst expectations of a $0.10 adjusted loss represents one of the largest consensus beats in the company's reporting history, driven by the iLink corneal cross-linking platform scaling faster than the market had modeled.
•The company reported no debt and approximately $339.8 million in liquid assets as of September 30, 2026, providing a balance-sheet cushion that is atypical for a mid-cap medical device company still in high-growth mode.
•GAAP gross margin of approximately 85% and non-GAAP gross margin of approximately 88% in Q3 2026 indicate a largely consumable-and-procedure revenue model with pricing power, which structurally supports margin expansion as volumes scale.
•The post-earnings share move of approximately 19.6% in after-hours trading illustrates the price-discovery risk unique to earnings events: large gaps can open at the session start, making pre-earnings position sizing a distinct risk management consideration for CFD traders.
•Preliminary 2027 net-sales guidance of approximately $1 billion, against a revised 2026 range of $775 million to $785 million, implies management's confidence in continued double-digit growth, though guidance at this horizon carries execution and reimbursement-environment risk.

Ownership

Top institutional holders (SEC Form 13F)

Top Institutional Holders

SEC 13F

The largest institutional shareholders, from SEC Form 13F filings — who holds the stock and how much.

Institution	Shares	Value	% of shares
BlackRock, Inc.	9.1M	$978.6M	15.36%
Janus Henderson Group PLC	5.3M	$575.8M	9.03%
Primecap Management Co.	3.4M	$362.9M	5.69%
Vanguard Portfolio Management LLC	3.2M	$345.4M	5.42%
Vanguard Capital Management LLC	2.5M	$270.1M	4.24%
State Street Corp.	2.2M	$235.0M	3.69%
Ameriprise Financial Inc.	1.6M	$173.4M	2.72%
Alliancebernstein L.P.	1.4M	$157.8M	2.36%
Citadel Advisors LLC	1.4M	$155.8M	2.44%
Holocene Advisors, LP	1.4M	$149.0M	2.34%

Source: SEC Form 13F filings · 335 institutional holders · as of 31-MAR-2026. 13F data is quarterly and lagged (filed ~45 days after quarter-end) and covers US institutional managers (>$100M AUM) only — not insiders, retail, or foreign holders. Not investment advice.

Understand the risks

Read before trading

Trading Risks

An honest, up-front list of the risks — both out of respect for the trader and as a YMYL compliance requirement.

Leverage / Liquidation

High leverage means a small adverse move can trigger forced liquidation and loss of your full margin.

High-valuation volatility

A high P/E stock is very sensitive to interest-rate and narrative shifts; swings can be large.

Session gaps

After-hours and weekend gaps; extended-hours liquidity is thinner than the regular session.

Basis risk

The CFD reference price can diverge from the exchange execution price.

Earnings volatility

Price swings widen around earnings dates and other scheduled disclosures.

Regulatory / event

Recalls, policy changes, or company-specific events can cause sharp moves.

Reference

FAQ & glossary

Sıkça Sorulan Sorular

Glaukos Corporation is a medical technology company focused on ophthalmology, developing and commercializing products for the treatment of eye diseases and conditions. Its portfolio spans two primary areas: surgical glaucoma devices and corneal health treatments. On the glaucoma side, Glaukos pioneered micro-invasive glaucoma surgery (MIGS) with its iStent family of devices, which are implanted during cataract surgery to reduce intraocular pressure. On the corneal health side, the company markets the iLink system for corneal cross-linking, a procedure used to treat progressive keratoconus and post-surgical corneal ectasia. Glaukos also has a pipeline of additional ophthalmic products in various stages of development. The company's commercial strategy centers on building a recurring revenue base through consumables and procedural products, particularly the pharmaceutical-device combination used in corneal cross-linking, which requires a new riboflavin solution for each treatment. This model distinguishes Glaukos from pure capital-equipment medical device firms.

Sözlük

Borsada işlem gören hisse senetleri ve CFD'lerin temel terimleri, her biri tek satırda: sayfanın hem okuyucular hem de yapay zekâ yanıt motorları için belirsizlikten uzak olması için.

Hisse senedi CFD'si	Bir hisse fiyatı üzerine fark sözleşmesi: yalnızca fiyat maruziyeti sağlar, dayanak hisselerin mülkiyetini vermez.
Uzatılmış işlem saatleri	Borsanın normal seansı dışında gerçekleşen açılış öncesi ve kapanış sonrası işlemler.
Baz riski	CFD referans fiyatı ile borsadaki gerçekleşme fiyatının aynı yönde hareket etmeme riski.
F/K	Fiyat/kazanç oranı = hisse fiyatı / hisse başına kazanç; yaygın bir değerleme ölçütü.
Brüt kâr marjı	Brüt kâr / gelir; ürün düzeyindeki kârlılığı yansıtır.
Hisse başına kazanç	Hisse başına kazanç = net kâr / seyreltilmiş dolaşımdaki hisse sayısı.

sembol

GKOS

Pazarlar

Hisse Senetleri

CU Ürün Kodu

GKOS

Etiketler

UK Court Crypto Sovereign SeizureUK Korea Bond Yield Inflation SurgeCoinbase UK Derivatives Exchange Launch

Sources & References

U.S. Securities and Exchange Commission (SEC)

Source Map

Every figure on this page traces to a primary or named third-party source. "As of" dates the source; "last checked" dates our most recent read of it.

Every figure here is also published as machine-readable data, and re-checked on a schedule so a stale one shows up as stale. View the raw data

Field	Value	Source	As of	Last checked
Reference price	live	CoinUnited stock CFD reference (live)	—	—	—
Market cap	$14B	CoinUnited reference x SEC shares	2026-11-01	2026-11-01	—
52-week range	$228.02 – $247.91	CoinUnited daily kline	—	2026-11-01	—
Next earnings	2027-02-16	Finnhub	—	2026-11-01	—
Quarterly revenue	$211M	SEC 10-Q	Q3 2026	2026-11-01	View
Net income	$2M	SEC 10-Q	Q3 2026	2026-11-01	View
Gross margin	85.2%	SEC 10-Q	Q3 2026	2026-11-01	View
Diluted EPS	$0.03	SEC 10-Q	Q3 2026	2026-11-01	View
Institutional ownership	10 top holders	SEC Form 13F	31-MAR-2026	2026-11-01	View
Analyst price targets	$218.70 consensus	Aggregated sell-side analyst consensus	2026-11-01	2026-11-01	—
Peer valuations	6 peers	Third-party ratios (FMP), trailing twelve months	2026-11-01	2026-11-01	—
Headquarters	San Clemente	Wikidata	—	2026-11-01	—
CoinUnited product	Stock CFD — price exposure, not equity (no voting; dividends reflected as adjustment); leverage available	CoinUnited product terms	—	2026-11-01	—
U.S. Securities and Exchange Commission (SEC)	—	U.S. Securities and Exchange Commission (SEC)	—	—	View

Yazar Hakkında

CoinUnited.io Research Team

This Glaukos Corporation page is compiled by CoinUnited.io's research team: analysts covering listed equities and global markets, working from primary filings and named third-party data rather than opinion.

Araştırma Metodolojimiz

Every figure is traced to a primary or named third-party source and dated: financial statements from the company’s SEC filings, institutional ownership from Form 13F, analyst targets from aggregated third-party coverage, and market data from the CoinUnited reference price. The Source Map on this page lists each one with its source and the date we last checked it.

Disclaimer: content is for informational and educational purposes only and is not personalized financial advice. A stock CFD carries significant risk and provides price exposure only, not equity ownership. Always conduct your own research and consult a qualified financial advisor.

Feragatnameler & Referanslar

Önemli Risk Uyarısı

A CoinUnited stock CFD gives price exposure to Glaukos Corporation only, not equity ownership: no shareholder voting rights, no dividends, and no settlement in the underlying share.

Leverage magnifies losses as well as gains, and a position can be liquidated long before the underlying share price recovers. The underlying listing trades on exchange hours, so the reference price can gap between sessions.

Kullanıcıların, herhangi bir yatırım kararı almadan önce kendi araştırmalarını yapmaları ve nitelikli finans profesyonellerine danışmaları önerilir. Bu platformun oluşturucuları ve işletmecileri, sağlanan bilgilere dayanarak oluşabilecek herhangi bir finansal kayıp veya diğer zararlar için hiçbir sorumluluk kabul etmezler.

Leveraged trading is extremely risky and you may lose your entire deposit.

Metodoloji Genel Bakış

Figures on this page are compiled from primary and named third-party sources, not produced by a forecasting model. Each one carries its source and date in the Source Map above.

Financial statements: the company’s own SEC filings (10-K / 10-Q), read from XBRL
Market data: the CoinUnited reference price and daily closes
Institutional ownership: SEC Form 13F quarterly filings
Analyst targets: aggregated third-party sell-side coverage — third-party opinion, not CoinUnited’s view
Peer multiples: third-party trailing-twelve-month ratios

CoinUnited does not publish a price forecast or target for Glaukos Corporation.

Son metodoloji gözden geçirmesi: